<p>Drug firm Zydus Cadila has received final approval from the US health regulator to market Cisatracurium Besylate Injection, a muscle relaxant given before general anaesthesia.</p>.<p>Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial, Cadila Healthcare said in a regulatory filing on Wednesday.</p>.<p>The drug will be manufactured at Liva plant of Cadila Healthcare Ltd.</p>.<p>Zydus Cadila is a part of the Cadila Healthcare group.</p>.<p>The group now has 297 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 377.60 apiece on BSE, 0.15 per cent lower against their previous close.</p>
<p>Drug firm Zydus Cadila has received final approval from the US health regulator to market Cisatracurium Besylate Injection, a muscle relaxant given before general anaesthesia.</p>.<p>Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP in the strength of 20 mg (base)/10 mL (2 mg/mL) multiple-dose vial, Cadila Healthcare said in a regulatory filing on Wednesday.</p>.<p>The drug will be manufactured at Liva plant of Cadila Healthcare Ltd.</p>.<p>Zydus Cadila is a part of the Cadila Healthcare group.</p>.<p>The group now has 297 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.</p>.<p>Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 377.60 apiece on BSE, 0.15 per cent lower against their previous close.</p>